After graduating from the University of Louvain-la-Neuve in Administration and Management and specializing in human resources, Jean-Paul Scheuren began his professional career with the Federation of Artisans; firstly, as an advisor, and later on becoming a deputy director, where he was responsible for the construction sector.
Read More
Scheuren’s passion for the Bio-Health industry began in 2005, when he launched Axoglia Therapeutics SA as an adviser, later becoming the CEO in 2006. The company is active in the development of innovative molecules in the neurodegenerative diseases field for diseases such as Alzheimer’s, Multiple Sclerosis, and Parkinson’s disease.
Scheuren worked with the Ministry of Economy and SNCI (Société Nationale de Crédit et d’Investissement) in the development of support programs for biotech companies in Luxembourg.
In 2009, he accepted the position of President in Luxembourg’s Biohealth Cluster to develop the life science sector as one of the pillars of economy locally. He has been witness to the impressive development of public research infrastructures and skills, followed today by a private sector, rendering Luxembourg a fertile host country for continuing life science endeavors.
Since 2012, he has been the founder and co-investor of the House of Bio-Health Project, which is hub playing host to innovative companies in Biotechnology, Clean-tech, and ICT-Health IT. The first phase of the project, which included 3,200m2 of laboratory space and 2,000m2 of offices, conferences, and meeting rooms, was inaugurated in mid-2014. Phase II of the House of Bio-Health Project, doubling the surface area of project, was inaugurated in 2017.
As an entrepreneur, he invests and assists regularly in the development and financing of life science start-ups. One of Scheuren’s last investments was in Doctena, a Health IT platform dedicated to booking appointments for health care professionals.